There are no RSV vaccines, but numerous drugmakers are working toward one, and some have reached promising results, including Pfizer and GSK.
A global study of 37,000 adults aged 60 and older found Moderna’s investigative vaccine was 83.7 effective against two or more symptoms of RSV-associated lower respiratory tract disease, and it was 82.4 percent effective against at least three symptoms. No safety concerns were noted, according to Moderna.
